Skip to main content
Industry News
Bayer's CKD treatment gets FDA priority review status

The FDA has granted priority review for Bayer's new drug application for its non-steroidal mineralocorticoid receptor inhibitor antagonist finerenone for treating diabetic kidney disease. The decision was based on the findings from the FIDELIO-DKD study that found finerenone effectively slowed the development of chronic kidney disease and lowered the risk for cardiovascular events in patients with type 2 diabetes.

Full Story: